US · Healthcare · Biotechnology
EPS came in at -1.97 against a street estimate of -1.47 — a miss of 34.0%.
Analysts rate Vaxcyte Inc a strong buy (10 buy, 1 hold, 0 sell out of 11) with an average price target of $117.00.
| Fund | Stake |
|---|---|
| FMR Inc | 14.01% |
| Jupiter Topco LLC | 12.07% |
| HHG PLC | 11.14% |
| T. Rowe Price Investment Management,Inc. | 8.20% |
| BlackRock Inc | 8.11% |
| RA Capital Management, LLC | 7.71% |
| Wellington Management Company LLP | 4.71% |
| Vanguard Portfolio Management, LLC | 4.43% |
| Document | Date |
|---|---|
| Material agreement · Q4 2026 HEADLINE NUMBERS • Vaxcyte completed concurrent equity and convertible-debt offerings on October 9, 2026. • Equity offering: 8,584,375 shares total, | 2026-10-09 |
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • Vaxcyte announced positive topline data from the Phase 3 OPUS-1 pivotal adult trial of VAX-31 on October 5, 2026. • VAX-31 is a 3 | 2026-10-05 |
| Board / officer change · Q3 2026 VAXCYTE, INC. - FORM 8-K SUMMARY Report Date: August 31, 2026 | Filed: September 3, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Company: Vaxcyte, Inc. | 2026-09-03 |
| Quarterly report · Q2 2026 VAXCYTE, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash Position: $183.2 million cash and cash equivalents as of June 30, 2026 (vs. $174.0 mill | 2026-08-05 |
| Results announced · Q3 2026 VAXCYTE Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and investments: $2,507.7 million as of June 30, 2026 (up from $ | 2026-08-05 |
| Board / officer change · Q3 2026 VAXCYTE, INC. – FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Vaxcyte, Inc. is a biopharmaceutical company incorporated in Delaware, trading on N | 2026-07-15 |
| Board / officer change · Q2 2026 VAXCYTE, INC. - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Vaxcyte, Inc. is a Delaware-incorporated company trading on Nasdaq under ticker sym | 2026-06-23 |
| Quarterly report · Q1 2026 VAXCYTE, INC. – Q1 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash Position: $260.8M in cash and equivalents plus $1.48B in short-term inv | 2026-05-06 |
Readable in the app.
| Announcement | Date |
|---|---|
| Narrows guidance for expected VAX-31 OPUS-1 topline data Vaxcyte, Inc. announced two executive appointments and narrowed guidance on a clinical trial timeline. David McAvoy was appointed as Chief Legal Officer, Chief Compliance Officer, and Corpor | 2026-09-03 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Vaxcyte Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.